Showing 5271-5280 of 6635 results for "".
- Castle Biosciences Supports Patient-Focused Initiatives for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-supports-of-patient-focused-initiatives-for-skin-cancer-awareness-month/2461182/Castle Biosciences, Inc. will continue its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month. “We a
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Diseasehttps://practicaldermatology.com/news/ready-for-prime-time-ampels-blood-tests-may-predict-drug-options-for-inflammatory-skin-disease/2461179/Ampel BioSolutions machine learning approach can characterize disease activity from gene expression data obtained from patient skin biopsy and may revolutionize the way doctors treat inflammatory skin diseases, according to research published in Science Advances. The lab test
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- New Colorescience, Aesthetics Biomedical Collabhttps://practicaldermatology.com/news/new-colorescience-aesthetics-biomedical-collab/2461177/Colorescience and Aesthetics Biomedical are launching a collaboration that combines Vivace Microneedle RF with a post-treatment protocol featuring Colorescience’s Sunforgettable Total Protection Brush-On Shield SPF 50. Patients opting for the radiofrequency microneedlin
- Chicago Dermatological Society to Host Art of Skin Gala to Advance Diversity, Equity, and Inclusionhttps://practicaldermatology.com/news/chicago-dermatological-society-to-host-art-of-skin-gala-to-advance-diversity-equity-and-inclusion/2461176/The Chicago Dermatological Society (CDS) is launching the Art of Skin Gala, sponsored by Janssen Biotech, Inc. The event, to be held June 10, is described as a live, in color celebration of diversity, equity, and inclusion brought to life through the beauty of skin. The
- ePatch Using Electrical Field Stimulation Shows Promise for Wound Healinghttps://practicaldermatology.com/news/epatch-using-electrical-field-stimulation-shows-promise-for-wound-healing/2461175/A “smart” flexible electric patch (ePatch) developed by a collaborative team from the Terasaki Institute for Biomedical Innovation promises to address the challenges posed by existing electrical field (EF) stimulation devices for wound healing and offers many uniquely advantageous fea
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- Milestone Alert: R2 Technologies Ships Out 100 GLACIAL Rx Deviceshttps://practicaldermatology.com/news/milestone-alert-r2-technologies-ships-out-100-glacial-devices/2461169/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont